1700015F17Rik Inhibitors
Chemical inhibitors of the protein 1700015F17Rik can play a significant role in modulating its function through the interruption of various cellular signaling pathways. Staurosporine, as a broad-spectrum protein kinase inhibitor, can inhibit the phosphorylation of numerous kinases that may be involved in regulating 1700015F17Rik. This can result in a widespread decrease in the protein's phosphorylation and activation status. Similarly, Bisindolylmaleimide I can inhibit protein kinase C, which, if responsible for phosphorylating 1700015F17Rik, would lead to a reduction in its phosphorylated state and thus its activity. LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases, can prevent the activation of the PI3K/AKT pathway. If 1700015F17Rik is an AKT substrate or its activity is PI3K/AKT-dependent, the inhibition by these chemicals would result in a decrease in 1700015F17Rik's activity. By the same token, PD98059 and U0126 can inhibit MEK1/2, leading to the blockade of the MAPK/ERK pathway. If 1700015F17Rik is downstream of this pathway, its activity would be reduced due to the lack of ERK activation.
Furthermore, Rapamycin can inhibit mTORC1, a key regulator of protein synthesis and cell growth, which could inhibit the function of 1700015F17Rik if it is mTORC1-dependent. SB203580 can target and inhibit p38 MAP kinase, decreasing the activation of its downstream targets which may include 1700015F17Rik. PP2, as an inhibitor of Src family tyrosine kinases, can prevent the phosphorylation of proteins within the Src kinase signaling pathways, potentially affecting 1700015F17Rik activity if it is associated with these pathways. SP600125, by inhibiting JNK, can lead to decreased activity of transcription factors regulated by JNK signaling, which can diminish the activity of 1700015F17Rik if it is a part of the JNK signaling cascade. Lastly, ZM-447439, an Aurora kinase inhibitor, can disrupt the cell cycle progression by inhibiting the function of Aurora kinases, which could lead to the inhibition of 1700015F17Rik if its activity is related to cell cycle control through Aurora kinases. Each of these inhibitors can affect the activity of 1700015F17Rik by targeting different kinases and signaling pathways that are crucial for its proper function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can inhibit a broad range of protein kinases. If 1700015F17Rik is known to be regulated by phosphorylation through specific kinases, staurosporine would inhibit those kinases, thereby inhibiting the phosphorylation and subsequent activation of 1700015F17Rik. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is an inhibitor of protein kinase C. Since protein kinase C is responsible for phosphorylating numerous proteins, the inhibition of this kinase by Bisindolylmaleimide I would lead to a decrease in the phosphorylation state of 1700015F17Rik, assuming 1700015F17Rik is a substrate for PKC, thereby inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 would prevent the activation of downstream targets, including AKT. If 1700015F17Rik activity is dependent on PI3K/AKT pathway signaling, LY294002 would result in its functional inhibition by blocking this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It would inhibit the PI3K/AKT pathway, similar to LY294002. Inhibition of this pathway would lead to a decrease in the phosphorylation and activity of downstream proteins, which may include 1700015F17Rik, thus functionally inhibiting it. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK/ERK pathway. Inhibition of MEK by PD98059 would prevent the activation of ERK and its downstream targets. Should 1700015F17Rik be a downstream effector of the MAPK/ERK pathway, its activity would be inhibited as a result of MEK inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 functions similarly to PD98059 by inhibiting MEK1/2, thereby blocking the MAPK/ERK signaling pathway. This would lead to a reduction in the phosphorylation of ERK and any of its potential downstream proteins, including 1700015F17Rik, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTORC1, a central component of the mTOR signaling pathway. This inhibition would lead to a reduction in protein synthesis and cell proliferation. If 1700015F17Rik functions are dependent on mTORC1 signaling, the inhibition of this pathway by rapamycin would inhibit the activity of 1700015F17Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. Inhibition of p38 MAPK would lead to decreased activation of downstream substrates and transcription factors. Assuming 1700015F17Rik activity is modulated by p38 MAPK signaling, its functional activity would be inhibited as a consequence of SB203580 application. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases phosphorylate various proteins, influencing signal transduction pathways. By inhibiting Src kinases, PP2 would prevent the phosphorylation of proteins that are part of Src kinase-dependent signaling pathways, potentially including 1700015F17Rik, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK by SP600125 would lead to a reduction in the phosphorylation of c-Jun and other transcription factors, which could decrease the transcription of genes regulated by JNK. If 1700015F17Rik is activated by JNK signaling, then its activity would be inhibited by SP600125. | ||||||